MedTrace Logo

RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.

NCT05127798 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-11-19

No results posted yet for this study

Summary

This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of Acute Myeloid Leukemia (AML) patients in the first line with intensive chemotherapy based regimens in Argentina.

Conditions

  • Acute Myeloid Leukemia, Adult

Interventions

OTHER

Evaluation of first line treatment with intensive treatment outcome in adult patients with AML.

Evaluation of first line treatment with intensive treatment outcome (or event free survival and overall survival and toxicity) in adult patients between 18 and 70 years old with AML.

Sponsors & Collaborators

  • Grupo Argentino de Tratamiento de la Leucemia Aguda

    lead OTHER

Principal Investigators

  • Maria Jose Mela Osorio, Dr. · Grupo Argentino de Tratamiento de la Leucemia Aguda

  • Hernan Dick, Dr. · Grupo Argentino de Tratamiento de la Leucemia Aguda

  • Isolda Fernandez, Dr. · Grupo Argentino de Tratamiento de la Leucemia Aguda

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2024-03-01
Completion
2024-12-01

Countries

  • Argentina

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05127798 on ClinicalTrials.gov